Achieve Life Sciences, Inc.: cytisinicline

(1) Following a CGMP inspection of Loey listed in this application, FDA conveyed deficiencies to the representative of the facility.

The facility should provide satisfactory responses to these deficiencies to the FDA office indicated on FDA Form 483 prior to your Complete Response submission.

Any additional specific details of these required postmarketing studies, including timetables and annual reporting requirements, will be described more fully in the approval letter for this application, if it is approved.

To support potential dosing recommendations for patients with ESRD, you should use modeling and simulation to characterize cytisinicline exposure across reasonably likely range of dialysis scenarios.